secwatch.observer — SEC 8-K summary
======================================

Issuer:     IVERIC bio, Inc. (—)
CIK:        0001410939
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001104659-23-053477
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Astellas to acquire IVERIC bio for $40/share in $5.9B all-cash deal
-------------------------------------------------------------------

- Astellas to acquire IVERIC bio for $40.00 per share in cash, a 64% premium to unaffected close of $24.33 on March 31, 2023.
- Total equity value approximately $5.9 billion based on ~148.2M fully diluted shares.
- ACP (avacincaptad pegol) NDA for geographic atrophy has PDUFA goal date of August 19, 2023 with priority review.
- Transaction expected to close in Q3 2023, subject to stockholder approval, HSR clearance, and other conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410939/000110465923053477/0001104659-23-053477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410939/000110465923053477/tm2314189d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-053477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer